RNS Number : 6187K
CVS Group plc
08 December 2025
 

08 December 2025

 

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

Transaction in own shares

 

CVS announces that on 05 December 2025 it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the terms of the share buyback programme announced on 24 October 2025 (the "Share Buyback Programme").

 

Date of purchase:

05/12/2025

Aggregate number of Ordinary Shares purchased:

12,974

Lowest price paid per share (GBp):

1,200.00

Highest price paid per share (GBp):

1,214.00

Volume weighted average price paid per share (GBp):

1,211.79


CVS intends to cancel all of the purchased Ordinary Shares.

 

Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 70,961,055 Ordinary Shares in issue and holds no Ordinary Shares in treasury.

 

The total number of voting rights in CVS is therefore 70,961,055 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

Since the commencement of the Share Buyback Programme, the Company has repurchased 779,728 Ordinary Shares in aggregate at a weighted average price of 1,215.61 pence per share.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback Programme.

 

Individual transactions:

 

Number of

Ordinary Shares purchased

Transaction price (GBp share)

Time of

transaction (UK Time)

Transaction

reference number

Trading Venue

 


204

1202

05/12/2025 08:02:59

1345897338243595

XLON


82

1200

05/12/2025 08:08:15

1345897338244424

XLON


459

1212

05/12/2025 08:49:22

1345897338249263

XLON


120

1208

05/12/2025 08:55:35

1345897338249854

XLON


72

1210

05/12/2025 08:59:59

1345897338250281

XLON


444

1210

05/12/2025 08:59:59

1345897338250285

XLON


82

1210

05/12/2025 09:26:59

1345897338253361

XLON


252

1214

05/12/2025 10:03:32

1345897338256451

XLON


124

1212

05/12/2025 10:24:34

1345897338257876

XLON


262

1214

05/12/2025 11:37:41

1345897338263129

XLON


196

1214

05/12/2025 12:29:44

1345897338266064

XLON


111

1214

05/12/2025 12:29:44

1345897338266067

XLON


201

1212

05/12/2025 12:49:13

1345897338267042

XLON


201

1212

05/12/2025 12:49:13

1345897338267048

XLON


43

1212

05/12/2025 12:49:13

1345897338267049

XLON


201

1212

05/12/2025 12:49:13

1345897338267050

XLON


63

1212

05/12/2025 12:49:13

1345897338267051

XLON


201

1212

05/12/2025 13:06:51

1345897338268072

XLON


72

1214

05/12/2025 13:06:51

1345897338268069

XLON


1180

1212

05/12/2025 13:06:51

1345897338268076

XLON


201

1212

05/12/2025 13:06:51

1345897338268077

XLON


263

1212

05/12/2025 13:06:51

1345897338268078

XLON


15

1212

05/12/2025 13:06:51

1345897338268079

XLON


146

1212

05/12/2025 13:25:57

1345897338268965

XLON


186

1212

05/12/2025 13:25:57

1345897338268963

XLON


6315

1212

05/12/2025 13:25:57

1345897338268969

XLON


201

1212

05/12/2025 13:25:57

1345897338268976

XLON


62

1212

05/12/2025 13:25:57

1345897338268977

XLON


201

1212

05/12/2025 13:25:57

1345897338268978

XLON


122

1212

05/12/2025 13:25:57

1345897338268980

XLON


466

1212

05/12/2025 13:25:57

1345897338268981

XLON


72

1214

05/12/2025 13:56:32

1345897338271298

XLON


147

1212

05/12/2025 13:59:26

1345897338271706

XLON


7

1212

05/12/2025 14:25:29

1345897338273806

XLON


 

Contacts

CVS Group plc                                                                                                                                                 via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Peel Hunt LLP (Nominated Adviser & Joint Broker)                                                                                 +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

 

Berenberg (Joint Broker)                                                                                                                             +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

 

Camarco (Financial PR)                                                                                                                            [email protected]

Ginny Pulbrook                                                                                                                                                +44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

 

About CVS Group plc (www.cvsukltd.co.uk)

 

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia.  CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

 

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSUPGPPPUPAPWM